331 related articles for article (PubMed ID: 23454976)
1. SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition.
Kershaw NJ; Murphy JM; Liau NP; Varghese LN; Laktyushin A; Whitlock EL; Lucet IS; Nicola NA; Babon JJ
Nat Struct Mol Biol; 2013 Apr; 20(4):469-76. PubMed ID: 23454976
[TBL] [Abstract][Full Text] [Related]
2. Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity.
Babon JJ; Kershaw NJ; Murphy JM; Varghese LN; Laktyushin A; Young SN; Lucet IS; Norton RS; Nicola NA
Immunity; 2012 Feb; 36(2):239-50. PubMed ID: 22342841
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for phosphotyrosine recognition by suppressor of cytokine signaling-3.
Bergamin E; Wu J; Hubbard SR
Structure; 2006 Aug; 14(8):1285-92. PubMed ID: 16905102
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of IL-6 family cytokines by SOCS3.
Babon JJ; Varghese LN; Nicola NA
Semin Immunol; 2014 Feb; 26(1):13-9. PubMed ID: 24418198
[TBL] [Abstract][Full Text] [Related]
5. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain.
Sasaki A; Yasukawa H; Suzuki A; Kamizono S; Syoda T; Kinjyo I; Sasaki M; Johnston JA; Yoshimura A
Genes Cells; 1999 Jun; 4(6):339-51. PubMed ID: 10421843
[TBL] [Abstract][Full Text] [Related]
6. Secondary structure assignment of mouse SOCS3 by NMR defines the domain boundaries and identifies an unstructured insertion in the SH2 domain.
Babon JJ; Yao S; DeSouza DP; Harrison CF; Fabri LJ; Liepinsh E; Scrofani SD; Baca M; Norton RS
FEBS J; 2005 Dec; 272(23):6120-30. PubMed ID: 16302975
[TBL] [Abstract][Full Text] [Related]
7. The biology and mechanism of action of suppressor of cytokine signaling 3.
Babon JJ; Nicola NA
Growth Factors; 2012 Aug; 30(4):207-19. PubMed ID: 22574771
[TBL] [Abstract][Full Text] [Related]
8. Reconstruction of an active SOCS3-based E3 ubiquitin ligase complex in vitro: identification of the active components and JAK2 and gp130 as substrates.
Kershaw NJ; Laktyushin A; Nicola NA; Babon JJ
Growth Factors; 2014 Feb; 32(1):1-10. PubMed ID: 24438103
[TBL] [Abstract][Full Text] [Related]
9. Mimetics of suppressor of cytokine signaling 3: Novel potential therapeutics in triple breast cancer.
La Manna S; Lee E; Ouzounova M; Di Natale C; Novellino E; Merlino A; Korkaya H; Marasco D
Int J Cancer; 2018 Nov; 143(9):2177-2186. PubMed ID: 29752723
[TBL] [Abstract][Full Text] [Related]
10. The structure of SOCS3 reveals the basis of the extended SH2 domain function and identifies an unstructured insertion that regulates stability.
Babon JJ; McManus EJ; Yao S; DeSouza DP; Mielke LA; Sprigg NS; Willson TA; Hilton DJ; Nicola NA; Baca M; Nicholson SE; Norton RS
Mol Cell; 2006 Apr; 22(2):205-16. PubMed ID: 16630890
[TBL] [Abstract][Full Text] [Related]
11. The molecular basis of JAK/STAT inhibition by SOCS1.
Liau NPD; Laktyushin A; Lucet IS; Murphy JM; Yao S; Whitlock E; Callaghan K; Nicola NA; Kershaw NJ; Babon JJ
Nat Commun; 2018 Apr; 9(1):1558. PubMed ID: 29674694
[TBL] [Abstract][Full Text] [Related]
12. The SOCS box domain of SOCS3: structure and interaction with the elonginBC-cullin5 ubiquitin ligase.
Babon JJ; Sabo JK; Soetopo A; Yao S; Bailey MF; Zhang JG; Nicola NA; Norton RS
J Mol Biol; 2008 Sep; 381(4):928-40. PubMed ID: 18590740
[TBL] [Abstract][Full Text] [Related]
13. Suppressor of Cytokine Signaling (SOCS) 5 utilises distinct domains for regulation of JAK1 and interaction with the adaptor protein Shc-1.
Linossi EM; Chandrashekaran IR; Kolesnik TB; Murphy JM; Webb AI; Willson TA; Kedzierski L; Bullock AN; Babon JJ; Norton RS; Nicola NA; Nicholson SE
PLoS One; 2013; 8(8):e70536. PubMed ID: 23990909
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses.
Varghese LN; Ungureanu D; Liau NP; Young SN; Laktyushin A; Hammaren H; Lucet IS; Nicola NA; Silvennoinen O; Babon JJ; Murphy JM
Biochem J; 2014 Mar; 458(2):395-405. PubMed ID: 24354892
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
Gao SM; Chen CQ; Wang LY; Hong LL; Wu JB; Dong PH; Yu FJ
Exp Hematol; 2013 Mar; 41(3):261-70.e4. PubMed ID: 23111066
[TBL] [Abstract][Full Text] [Related]
16. Deletion of the SOCS box of suppressor of cytokine signaling 3 (SOCS3) in embryonic stem cells reveals SOCS box-dependent regulation of JAK but not STAT phosphorylation.
Boyle K; Zhang JG; Nicholson SE; Trounson E; Babon JJ; McManus EJ; Nicola NA; Robb L
Cell Signal; 2009 Mar; 21(3):394-404. PubMed ID: 19056487
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant.
Funakoshi-Tago M; Tsuruya R; Ueda F; Ishihara A; Kasahara T; Tamura H; Tago K
Cytokine; 2019 Nov; 123():154753. PubMed ID: 31255914
[TBL] [Abstract][Full Text] [Related]
18. Regulation of Janus kinases by SOCS proteins.
Kershaw NJ; Murphy JM; Lucet IS; Nicola NA; Babon JJ
Biochem Soc Trans; 2013 Aug; 41(4):1042-7. PubMed ID: 23863176
[TBL] [Abstract][Full Text] [Related]
19. Role of the cytokine-inducible SH2 protein CIS in desensitization of STAT5b signaling by continuous growth hormone.
Ram PA; Waxman DJ
J Biol Chem; 2000 Dec; 275(50):39487-96. PubMed ID: 10991939
[TBL] [Abstract][Full Text] [Related]
20. SOCS3 promotes inflammation and apoptosis via inhibiting JAK2/STAT3 signaling pathway in 3T3-L1 adipocyte.
Liu Z; Gan L; Zhou Z; Jin W; Sun C
Immunobiology; 2015 Aug; 220(8):947-53. PubMed ID: 25720636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
